PMID- 33073612
OWN - NLM
STAT- MEDLINE
DCOM- 20210218
LR  - 20210218
IS  - 1536-8386 (Electronic)
IS  - 1536-8386 (Linking)
VI  - 40
IP  - 1
DP  - 2021 Jan 2
TI  - Infusion of HLA-matched and static magnetic field-exposed allogenic lymphocytes 
      treating lymphocytopenia and cytokine storm syndrome: A treatment proposal for 
      COVID-19 patients.
PG  - 11-25
LID - 10.1080/15368378.2020.1830290 [doi]
AB  - Among haematological parameters of patients seriously ill with the coronavirus 
      infectious disease 2019 (COVID-19), leucocytosis, lymphocytopenia, and the 
      abnormal release of circulating cytokines, termed cytokine storm syndrome (CSS, 
      also known as cytokine release syndrome or CRS), were found associated with 
      disease severity. In particular, according to the serum cytokine profiling, 
      pro-inflammatory interleukin 6 (IL-6) and anti-inflammatory interleukin 10 
      (IL-10) were observed to be considerably higher in patients experiencing 
      respiratory distress, septic shock and/or multi-organ failure, namely "critical 
      cases" requiring intensive care unit (ICU) admission, very often resulting in 
      death. Interestingly, the production of these cytokines from human lymphocytes 
      was found to be modulated by exposure of 24 h to a 554.2-553.8 mT inhomogeneous 
      static magnetic field (SMF), which elicits IL-10 and suppresses IL-6. Thus, 
      herein, with the aim of restoring lymphocyte count and physiological serum levels 
      of IL-6 and IL-10, the infusion of human leukocyte antigen (HLA)-matched and 
      SMF-exposed allogenic lymphocytes is proposed for the first time as an easy and 
      affordable treatment option for COVID-19 patients. Even if the count of 
      lymphocytes in COVID-19 patients is very low, SMF exposure may be a valuable tool 
      for reprogramming autologous lymphocytes towards physiological conditions. 
      Furthermore, the same procedure could be extended to include the whole autologous 
      or allogenic white blood cells (WBCs). Time-varying/pulsed magnetic fields 
      exerting comparable cell effects could also be employed.
FAU - Vergallo, Cristian
AU  - Vergallo C
AUID- ORCID: 0000-0002-0264-4753
AD  - Department of Pharmacy, University of Chieti-Pescara "G. d'Annunzio" , Chieti, 
      Italy.
LA  - eng
PT  - Journal Article
DEP - 20201017
PL  - England
TA  - Electromagn Biol Med
JT  - Electromagnetic biology and medicine
JID - 101133002
RN  - 0 (HLA Antigens)
RN  - 0 (Interleukin-6)
SB  - IM
MH  - COVID-19/*complications
MH  - Cytokine Release Syndrome/complications/immunology/pathology/*therapy
MH  - HLA Antigens/*immunology
MH  - Humans
MH  - Immunotherapy
MH  - Interleukin-6/chemistry/metabolism
MH  - Lymphocytes/*cytology/immunology
MH  - Lymphopenia/complications/immunology/pathology/*therapy
MH  - *Magnetic Fields
MH  - Models, Molecular
MH  - Protein Conformation
MH  - Signal Transduction/immunology
OTO - NOTNLM
OT  - Coronavirus infectious disease 2019 (COVID-19)
OT  - donor lymphocyte infusion (DLI)
OT  - human leukocyte antigen (HLA)
OT  - interleukin 10 (IL-10)
OT  - interleukin 6 (IL-6)
OT  - lymphocytes
OT  - lymphocytopenia
OT  - static magnetic field (SMF)
EDAT- 2020/10/20 06:00
MHDA- 2021/02/20 06:00
CRDT- 2020/10/19 08:39
PHST- 2020/10/20 06:00 [pubmed]
PHST- 2021/02/20 06:00 [medline]
PHST- 2020/10/19 08:39 [entrez]
AID - 10.1080/15368378.2020.1830290 [doi]
PST - ppublish
SO  - Electromagn Biol Med. 2021 Jan 2;40(1):11-25. doi: 10.1080/15368378.2020.1830290. 
      Epub 2020 Oct 17.